Drugs News and Research

RSS

Inflammation causally linked to functional decline in aging

Inflammation is the common denominator of many chronic age-related diseases such as arthritis, gout, Alzheimer's, and diabetes. But according to a Yale School of Medicine study, even in the absence of a disease, inflammation can lead to serious loss of function throughout the body, reducing healthspan - that portion of our lives spent relatively free of serious illness and disability.

23 Oct 2013

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California.

23 Oct 2013

Fatty acid entry into cells happens by diffusion

The current global epidemic of obesity-linked diabetes and its associated consequences -cardiovascular, neurological and renal diseases - is a growing public health problem for which therapeutic options are limited.

23 Oct 2013

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.

23 Oct 2013

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.

23 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

The U.S. Food and Drug Administration is alerting hospitals, health care providers, veterinarians, and patients of a voluntary recall of certain human and veterinary products produced and distributed for sterile use by Specialty Medicine Compounding Pharmacy of South Lyon, Mich.

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

U of T researchers develop method to screen human stem cells

University of Toronto researchers have developed a method that can rapidly screen human stem cells and better control what they will turn into. The technology could have potential use in regenerative medicine and drug development. Findings are published in this week's issue of the journal Nature Methods.

23 Oct 2013

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

23 Oct 2013

Study examines association between suicidal vulnerability and analgesic consumption in elderly

A paper published in the current issue of Psychotherapy and Psychosomatics has investigated the relationship between pain killers and suicidal behavior in the elderly.

23 Oct 2013

Prognostic factors could aid RCC metastasectomy decisions

Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma.

22 Oct 2013

Amgen Buys Roche Rights To Neutropenia Drugs

...

22 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

PDL Biopharma Acquires Diabetes Royalty, Milestone Rights For $240.5M

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring.

22 Oct 2013

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc., a multi-specialty health care company headquartered in Irvine, California.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

COPD treatments: an interview with Professor Price, University of Aberdeen

The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.

22 Oct 2013

Drugs News and Research

Inflammation causally linked to functional decline in aging

Promising technique for treating eye disease proves effective in preclinical studies

Fatty acid entry into cells happens by diffusion

Scientists reveal first comprehensive genomic analysis of aggressive lymphomas

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

U of T researchers develop method to screen human stem cells

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Study examines association between suicidal vulnerability and analgesic consumption in elderly

Prognostic factors could aid RCC metastasectomy decisions

Amgen Buys Roche Rights To Neutropenia Drugs

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

PDL Biopharma Acquires Diabetes Royalty, Milestone Rights For $240.5M

Novozymes Biopharma partners with Almac to provide combined service for drug development

Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

InnoCore, Allergan expand collaboration to develop ophthalmology medicines

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

COPD treatments: an interview with Professor Price, University of Aberdeen

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News